Project Grant HT94252510505
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$3.2M
Federal Agency
Defense Health Agency
Awardee
Eg427 (TTTFQ5CCENH4)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
France
Similar Awards
The Defense Health Agency awarded Epicentrx Inc. a $385,536 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program. The funding supports the development and translation of a multimodal therapeutic agent and medical countermeasure for the treatment of military-related toxic exposures. The project will be conducted over a 3-year period from September 1, 2024 to August 31, 2027. The research aims to transform healthcare for military service members and...
The Defense Health Agency awarded a $1,523,243 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Medstar Health Research Institute Inc. to evaluate the use of intravesical gentamicin coupled with the probiotic Lactobacillus rhamnosus for improving urinary health. The project will involve pre-clinical studies at Loyola University of Chicago and the University of Pittsburgh to determine the optimal administration protocols, as well as a pilot clinical...
The Department of the Army Medical Command, through the Military Medical Research and Development (CFDA 12.420) federal grant program, awarded Encephalogix, Inc. a $459,994 Project Grant to support epilepsy research. The award, effective from Sep 1, 2024 to Aug 31, 2025, will fund the company's "Epilepsy Research Program Idea Development Award" to explore innovative approaches to the prevention, diagnosis, treatment, and management of epilepsy, a condition relevant to military...
Emory University will conduct research under a $1,255,611 Project Grant from the Defense Health Agency through the Military Medical Research and Development program. The three-year award beginning in April 2023 will fund research to define the molecular basis for immunogenicity of locally advanced prostate tumors resistant to androgen deprivation therapy. The CFDA 12.420 program supports basic, applied and advanced biomedical research to transform military and public health care through...
This federal Project Grant award, valued at $860,998.00 and issued by the Defense Health Agency, supports research under the Military Medical Research and Development (CFDA 12.420) program. The grant funds the University of California, San Francisco to conduct advanced research on the "Neurophysiology of Post-Traumatic Epilepsy: Unraveling Epileptogenesis Signals Biomarkers" over a 3-year period from April 1, 2025 to March 31, 2028. This research aims to transform healthcare for...
The U.S. Defense Health Agency awarded a $1,354,543 Project Grant to The University of Texas MD Anderson Cancer Center to conduct a Phase 1 clinical trial of an engineered oncolytic herpes simplex virus-1 (HSV-1) M032 in newly diagnosed diffuse midline glioma patients. The award is funded under the Military Medical Research and Development (CFDA 12.420) program, which supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader...
The U.S. Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) awarded a $199,908 Project Grant to the Institut National De La Sante Et De La Recherche Medicale (Inserm) to model hemangioblastomas using induced pluripotent stem cells carrying mutations in the von Hippel-Lindau gene. This 2-year project, scheduled for completion by April 30, 2026, aims to transform healthcare for Service Members and the American public through innovative biomedical research. As a...
This federal Project Grant award of $345,664.00 from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, supports an advanced biomedical research initiative led by Royal Holloway University of London. The research project aims to develop an AAV-based microdystrophin gene therapy for Duchenne muscular dystrophy, with a focus on enhancing immune protection through capsid bioengineering. The award period spans from December 1, 2024 to November 30,...
This Project Grant from the Defense Health Agency provides $734,781 to Formation Venture Engineering Foundry Inc. for precision medicine immunotherapy research under the Military Medical Research and Development program (CFDA 12.420). The research aims to develop medical solutions for treating neurodegeneration in amyotrophic lateral sclerosis patients who test positive for human endogenous retrovirus K. The awardee will conduct applied and advanced biomedical research from June 2023 through...
The U.S. Defense Health Agency awarded a $1,332,764 Project Grant to Neurocreis, Inc. in College Station, TX under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, effective July 1, 2025 through June 30, 2028, supports the therapeutic development of NC101 for promoting neurological recovery after chronic spinal cord injury. The grant funding will enable Neurocreis to conduct advanced biomedical research initiatives focused on transforming healthcare...